SlideShare une entreprise Scribd logo
1  sur  41
Neurocommunication

   Brian J. Piper, Ph.D.
Terminology
• Neurotransmitter: chemical that is released in
  the brain and has an effect on a local target
• Hormone: chemical that is released into
  bloodstream that has an effect on a distant
  target
Goals
• Neurotransmission
  – History
  – Onset: Neurotransmitter release (classical and
    non-classical)
  – Offset: autoreceptors, transporters, enzymes
  – Receptor Families
• Endocrine
History: Golgi vs. Cajal
• Italian physician
• Reticulum theory
• Silver stain




                          Camillo Golgi (1843-1926)
Controversy: Golgi vs. Cajal
                          • Santiogo Ramon y Cajal
                               – Neuroanatomist
                               – Used Golgi’s technique
                               – Neuron theory




1852-1934



                Chicken cerebellum
Neural Communication
 The body’s information system is built from
billions of interconnected cells called neurons.
   Communication between neurons is both
             electrical and chemical.
Otto Loewi
• Discovered “Vagusstoff” later
  known as acetylcholine
• “father of neuroscience”
• Nobel Prize 1936
What are amino acids?
• Amine (NH2) + Carboxyl ( -COOH)
• 20 total, 9 essential




                    tyrosine        Tryptophan
More terminology
• Peptides: short (<50) strings of amino acids,
  Valine-Glycine-Serine-Alanine… e.g. NPY




                                    C terminal: COOH
                                    N terminal: NH2
                                    Arginine, Proline, Lysine, Phenylalanine,
                                    Methionine, Histidine, Aspartic Acid, Valine
More terminology
• Peptides: short (<50) strings of amino acids,
  Valine-Glycine-Serine-Alanine… e.g. NPY
More terminology
Proteins: longer strings of amino acids, have 3-D
structure, form receptors, transporters
Comparison
                     Peptide             Protein
Size (amino acids)   < 40                >40
Dimensions           1-D                 3-D
Complexity           Low                 High




                            Hemoglobin
“Typical” Synapse
Electron Microscope
• Beams of electrons are presented to a thin
  section, 50 pm (10-12) resolution
• Reveals different types of Synapses
Dendritic Spine
Axodendritic Synapse
Axosomatic Synapse
Neurotransmitter Criteria
•    1) Found and made presynaptically.
•    2) Mechanism for inactivation.
•    3) Stimulating neuron releases it.
•    4) Receptors found postsynaptically.
•    5) Applying substance has biological effect.
•    6) Antagonizing inhibits biological effect.



    “neuromodulators”
Neurotransmitter Comparison
                Classical   Non-Classical
Discovery       1950’s      1980’s
Concentration   High        Low
#               Few         Many
Synthesis       Anywhere    Soma
Classical Neurotransmitters
• Monoamines: dopamine, norepinephrine,
  serotonin
• Acetylcholine (ACh)
• Amino Acids: glycine, GABA, Glutamate
Non-classical Neurotransmitters
• Peptides: Corticotropin-releasing factor (CRF),
  endorphins
• Lipids: Anandamide
• Gases: Nitric Oxide
Co-Transmitters
  Amine/Amino Acid                             Peptide
  Dopamine                                     Cholecystokinin (CCK)
  Norepinephrine                               enkephalin
  Epinephrine                                  neurotensin
  Serotonin                                    substance P
  Acetylcholine                                somatostatin
  Gamma aminobutyric acid (GABA)               motilin




Stahl, S. (2000). Essential Psychopharmacology, p. 20.
Axon Terminal
Brakes II
• Autoreceptors: this receptor (“auto” = “self”)
  can act to inhibit further neurotransmitter
  release
  – Terminal (axon) autoreceptors: inhibit
    neurotransmitter release
  – Somatodendritic autoreceptors: reduce rate of
    action potentials
Brakes I
• Enzyme: A + B __ENZ____> AB
• Enzyme: CD    __ENZ____> C + D
Transporters
• Proteins that move molecule from one place
  to another, examples:
  – SERT: serotonin transporter
  – NET: norepinephrine transporter
  – DAT: dopamine transporter



                            Inside
                            ----------------------------------------------------------------------
                            Outside
Post-synaptic
• Ligand: substance that binds to a receptor
• Ion: atom where # electrons ≠ # protons
  – Ca2+ Na+     K+
  – Cl-
• First messenger: neurotransmitter
• Second messenger: other molecule
• Kinase: enzyme that adds phosphate (PO4)
Types of Receptors
So Many Receptors!
           Serotonin (5-HT):
           1
           2
           3
           4
           5
           6
           7
Family 1: Ionotropic
• Binding to receptor opens channel to let ions
  in (aka: ligand gated ion receptors)
Family 1: Ionotropic
  • Binding to receptor opens channel to let ions
    in (aka: ligand gated ion receptors)




0:40 – 6:20: http://www.youtube.com/watch?v=8jPH2pKzIDY
Family 2: Metabotropic (2nd messenger)
• Steps:
• 1) Ligand binds receptor
• 2) G protein acts on enzyme
• 3) Enzyme regulates 2nd
  messenger
• 4) 2nd messenger acts on
      protein kinase

    6:30-9:00 http://www.youtube.com/watch?v=8jPH2pKzIDY
Family 2: Metabotropic (Channel)
• Steps:
• 1) Ligand binds receptor
• 2) G protein alters
  channel
• 3) ions flow out of
   neuron
Receptor Families Compared
                 Ionotropic                 Metabotropic
Subunits         4-5                        1
Mechanism        Simple: Channel opening    Complex: G protein cascade
2nd messengers   No                         Yes
Speed            Fast                       Slow




                                           Meyer & Quenzer (2005). p 73
Family 3: Tyrosine Kinase
• Steps:
1) Ligand (BDNF) binds to Trk receptor
2) Trk receptors come together, and
phosphorylate each other
So many drug targets!!!
                  Examples:
                  1) Tryptophan
                  6) Nicotine
                  10) MAO-I
                  11) SSRIs
Endocrine System
Gland      Hormone (Function)
Pineal     Melatonin (light-dark rhythm)
Thyroid    T3/T4 (energy)
Adrenal    Cortisol (stress)
Pancreas   Insulin (glucose)
Ovaries    Estrogens (2nd sex characteristics)
Testes     Androgens (2nd sex characteristics)
Example
    • Rats that received ecstasy (MDMA) during
      adolescence were more sensitive to a 5-HT2
      agonist when adults




Biezonski et al. (2009). Brain Research, 1252, 87-93.
Reference

Contenu connexe

Tendances

Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseAnupam dubey
 
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & SymptomsAnti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & SymptomsChetan Prakash
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugsBindu Pulugurtha
 
Non adrenergic and Non cholinergic transmission
Non adrenergic and Non cholinergic transmission Non adrenergic and Non cholinergic transmission
Non adrenergic and Non cholinergic transmission E Poovarasan
 
Screening of Anxiolytics
Screening of AnxiolyticsScreening of Anxiolytics
Screening of AnxiolyticsDr. Advaitha MV
 
Neurohumoral transmission in ANS ( autonomic nervous system) updated
Neurohumoral transmission in ANS ( autonomic nervous system) updatedNeurohumoral transmission in ANS ( autonomic nervous system) updated
Neurohumoral transmission in ANS ( autonomic nervous system) updatedGVamsiYadav
 
Cns stimulants and depressants screening models
Cns stimulants and depressants screening modelsCns stimulants and depressants screening models
Cns stimulants and depressants screening modelsDRASHTI PATEL
 
Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Divya Krishnan
 
screening of anxiolytics
screening of anxiolyticsscreening of anxiolytics
screening of anxiolyticsSayanti Sau
 
Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...DHINESHKUMAR V
 
neurohumoral transmission in cns
neurohumoral transmission in cnsneurohumoral transmission in cns
neurohumoral transmission in cnsRavi Kumar katukuri
 
Preclinical screening of antiallergics
Preclinical screening of antiallergicsPreclinical screening of antiallergics
Preclinical screening of antiallergicsPrajitha p
 
screening model for parkinsons disease
screening model for parkinsons diseasescreening model for parkinsons disease
screening model for parkinsons diseaseKundlik Rathod
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agentSONALPANDE5
 
Preclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityPreclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityShrutiGautam18
 
Neurotransmission | Neuromodulation | Mechanism | Disorders
Neurotransmission | Neuromodulation |  Mechanism | DisordersNeurotransmission | Neuromodulation |  Mechanism | Disorders
Neurotransmission | Neuromodulation | Mechanism | DisordersChetan Prakash
 
Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxinRashmi116
 
Screening of antiepileptic drugs
Screening of antiepileptic drugsScreening of antiepileptic drugs
Screening of antiepileptic drugsKanthlal SK
 

Tendances (20)

Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's Disease
 
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & SymptomsAnti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
Anti-Ischemics | Mechanism | Ischemia | Signs & Symptoms
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugs
 
Non adrenergic and Non cholinergic transmission
Non adrenergic and Non cholinergic transmission Non adrenergic and Non cholinergic transmission
Non adrenergic and Non cholinergic transmission
 
Screening of Anxiolytics
Screening of AnxiolyticsScreening of Anxiolytics
Screening of Anxiolytics
 
Neurohumoral transmission in ANS ( autonomic nervous system) updated
Neurohumoral transmission in ANS ( autonomic nervous system) updatedNeurohumoral transmission in ANS ( autonomic nervous system) updated
Neurohumoral transmission in ANS ( autonomic nervous system) updated
 
Cns stimulants and depressants screening models
Cns stimulants and depressants screening modelsCns stimulants and depressants screening models
Cns stimulants and depressants screening models
 
Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan
 
screening of anxiolytics
screening of anxiolyticsscreening of anxiolytics
screening of anxiolytics
 
Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...Relationship between drug concentration and effect and quantitative aspects o...
Relationship between drug concentration and effect and quantitative aspects o...
 
neurohumoral transmission in cns
neurohumoral transmission in cnsneurohumoral transmission in cns
neurohumoral transmission in cns
 
Preclinical screening of antiallergics
Preclinical screening of antiallergicsPreclinical screening of antiallergics
Preclinical screening of antiallergics
 
screening model for parkinsons disease
screening model for parkinsons diseasescreening model for parkinsons disease
screening model for parkinsons disease
 
Screening of antiparkinson agent
Screening of antiparkinson agentScreening of antiparkinson agent
Screening of antiparkinson agent
 
Preclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activityPreclinical screening of new substance for pharmacological activity
Preclinical screening of new substance for pharmacological activity
 
Neurotransmission | Neuromodulation | Mechanism | Disorders
Neurotransmission | Neuromodulation |  Mechanism | DisordersNeurotransmission | Neuromodulation |  Mechanism | Disorders
Neurotransmission | Neuromodulation | Mechanism | Disorders
 
Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
 
NEURO DEGENERATIVE DISEASES
NEURO DEGENERATIVE DISEASESNEURO DEGENERATIVE DISEASES
NEURO DEGENERATIVE DISEASES
 
Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxin
 
Screening of antiepileptic drugs
Screening of antiepileptic drugsScreening of antiepileptic drugs
Screening of antiepileptic drugs
 

En vedette

Neuropharmacology: Schizophrenia
Neuropharmacology: SchizophreniaNeuropharmacology: Schizophrenia
Neuropharmacology: SchizophreniaBrian Piper
 
INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism
INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism
INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism pharmdude
 
Schizofrenia e patologia mentale grave
Schizofrenia e patologia mentale graveSchizofrenia e patologia mentale grave
Schizofrenia e patologia mentale graveRaffaele Barone
 
Schizofrenia e patologia mentale grave
Schizofrenia e patologia mentale graveSchizofrenia e patologia mentale grave
Schizofrenia e patologia mentale graveRaffaele Barone
 
Neuropharmacology: Inhalants
Neuropharmacology: InhalantsNeuropharmacology: Inhalants
Neuropharmacology: InhalantsBrian Piper
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Brian Piper
 
Il Cervello Umano
Il Cervello UmanoIl Cervello Umano
Il Cervello Umanolab13unisa
 
Pharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersPharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersBrian Piper
 
Migraine and 5-HT
Migraine and 5-HTMigraine and 5-HT
Migraine and 5-HTBrian Piper
 
Pathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IPathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IBrian Piper
 
Pharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons diseasePharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons diseaseBrian Piper
 
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADPsychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADBrian Piper
 
Neurotransmission
NeurotransmissionNeurotransmission
NeurotransmissionBrian Piper
 
Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Brian Piper
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettesBrian Piper
 
Neuropharmacology: Hallucinogens
Neuropharmacology: HallucinogensNeuropharmacology: Hallucinogens
Neuropharmacology: HallucinogensBrian Piper
 
Neuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic gangliaNeuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic gangliaBrian Piper
 

En vedette (20)

Neuropharmacology: Schizophrenia
Neuropharmacology: SchizophreniaNeuropharmacology: Schizophrenia
Neuropharmacology: Schizophrenia
 
INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism
INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism
INTRODUCTION TO AUTONOMIC PHARMACOLOGY Part III - Mechanism
 
Tokoh psikologi
Tokoh psikologiTokoh psikologi
Tokoh psikologi
 
Schizofrenia e patologia mentale grave
Schizofrenia e patologia mentale graveSchizofrenia e patologia mentale grave
Schizofrenia e patologia mentale grave
 
Schizofrenia e patologia mentale grave
Schizofrenia e patologia mentale graveSchizofrenia e patologia mentale grave
Schizofrenia e patologia mentale grave
 
Neuropharmacology: Inhalants
Neuropharmacology: InhalantsNeuropharmacology: Inhalants
Neuropharmacology: Inhalants
 
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
 
Il Cervello Umano
Il Cervello UmanoIl Cervello Umano
Il Cervello Umano
 
Schizophrenia
SchizophreniaSchizophrenia
Schizophrenia
 
Pharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disordersPharmacotherapies for neurodegenerative disorders
Pharmacotherapies for neurodegenerative disorders
 
Migraine and 5-HT
Migraine and 5-HTMigraine and 5-HT
Migraine and 5-HT
 
Pathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part IPathophysiology: Neuroanatomy Part I
Pathophysiology: Neuroanatomy Part I
 
Pharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons diseasePharmacotherapies for parkinsons disease
Pharmacotherapies for parkinsons disease
 
ADHD Drugs
ADHD DrugsADHD Drugs
ADHD Drugs
 
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SADPsychopharmacology of Anxiety Disorders I: GAD & SAD
Psychopharmacology of Anxiety Disorders I: GAD & SAD
 
Neurotransmission
NeurotransmissionNeurotransmission
Neurotransmission
 
Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014Drug Abuse & Society (RX 462) Presentations-Spring 2014
Drug Abuse & Society (RX 462) Presentations-Spring 2014
 
electronic cigarettes
electronic cigaretteselectronic cigarettes
electronic cigarettes
 
Neuropharmacology: Hallucinogens
Neuropharmacology: HallucinogensNeuropharmacology: Hallucinogens
Neuropharmacology: Hallucinogens
 
Neuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic gangliaNeuromuscular junction & autonomic ganglia
Neuromuscular junction & autonomic ganglia
 

Similaire à Neuropharmacology: Neurotransmission

Role of Neurotransmitters with their detailed description
Role of Neurotransmitters with their detailed descriptionRole of Neurotransmitters with their detailed description
Role of Neurotransmitters with their detailed descriptionAwanish Mishra
 
An Introduction to Neurotransmitter System
An Introduction to Neurotransmitter SystemAn Introduction to Neurotransmitter System
An Introduction to Neurotransmitter SystemMadan Baral
 
Neurochemistry
NeurochemistryNeurochemistry
NeurochemistryMahin Nwx
 
Neurotransmiters of ans synthesis and fate
Neurotransmiters of ans  synthesis and fateNeurotransmiters of ans  synthesis and fate
Neurotransmiters of ans synthesis and fateZulcaif Ahmad
 
Neurotransmission ubc
Neurotransmission ubcNeurotransmission ubc
Neurotransmission ubcYazeedMD
 
BCM-Neurochemistry.pdf
BCM-Neurochemistry.pdfBCM-Neurochemistry.pdf
BCM-Neurochemistry.pdfDamiJunior
 
Y1S2 Synapse NMJ Neurotransmitters
Y1S2 Synapse NMJ NeurotransmittersY1S2 Synapse NMJ Neurotransmitters
Y1S2 Synapse NMJ Neurotransmittersvajira54
 
97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf
97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf
97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdfboscokiuria
 
Signal transmission at synapse
Signal transmission at synapseSignal transmission at synapse
Signal transmission at synapseAnimesh Roy
 
Overview of the Nervous System.pptx
Overview of the Nervous System.pptxOverview of the Nervous System.pptx
Overview of the Nervous System.pptxLivson Thomas
 
Nerve transmission
Nerve transmissionNerve transmission
Nerve transmissionBangaluru
 
Nerve transmission
Nerve transmissionNerve transmission
Nerve transmissionBangaluru
 

Similaire à Neuropharmacology: Neurotransmission (20)

Cell signaling
Cell signalingCell signaling
Cell signaling
 
NTs_2.ppt
NTs_2.pptNTs_2.ppt
NTs_2.ppt
 
Nerurons.ppt
Nerurons.pptNerurons.ppt
Nerurons.ppt
 
Role of Neurotransmitters with their detailed description
Role of Neurotransmitters with their detailed descriptionRole of Neurotransmitters with their detailed description
Role of Neurotransmitters with their detailed description
 
An Introduction to Neurotransmitter System
An Introduction to Neurotransmitter SystemAn Introduction to Neurotransmitter System
An Introduction to Neurotransmitter System
 
Neurochemistry
NeurochemistryNeurochemistry
Neurochemistry
 
Neurotransmiters of ans synthesis and fate
Neurotransmiters of ans  synthesis and fateNeurotransmiters of ans  synthesis and fate
Neurotransmiters of ans synthesis and fate
 
Neurotransmission ubc
Neurotransmission ubcNeurotransmission ubc
Neurotransmission ubc
 
Ch 11c
Ch 11cCh 11c
Ch 11c
 
Ch 11c
Ch 11cCh 11c
Ch 11c
 
CNS.ppt
CNS.pptCNS.ppt
CNS.ppt
 
BCM-Neurochemistry.pdf
BCM-Neurochemistry.pdfBCM-Neurochemistry.pdf
BCM-Neurochemistry.pdf
 
Y1S2 Synapse NMJ Neurotransmitters
Y1S2 Synapse NMJ NeurotransmittersY1S2 Synapse NMJ Neurotransmitters
Y1S2 Synapse NMJ Neurotransmitters
 
97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf
97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf
97308319-Neurotransmitter-and-Its-Synapses-Ppt.pdf
 
Signal transmission at synapse
Signal transmission at synapseSignal transmission at synapse
Signal transmission at synapse
 
Overview of the Nervous System.pptx
Overview of the Nervous System.pptxOverview of the Nervous System.pptx
Overview of the Nervous System.pptx
 
Cell physiology1.
Cell physiology1.Cell physiology1.
Cell physiology1.
 
snaptic transmission.pptx
snaptic transmission.pptxsnaptic transmission.pptx
snaptic transmission.pptx
 
Nerve transmission
Nerve transmissionNerve transmission
Nerve transmission
 
Nerve transmission
Nerve transmissionNerve transmission
Nerve transmission
 

Plus de Brian Piper

Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Brian Piper
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Brian Piper
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IIBrian Piper
 
Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part IBrian Piper
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for BipolarBrian Piper
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDBrian Piper
 
Antipsychotics Part II
Antipsychotics Part IIAntipsychotics Part II
Antipsychotics Part IIBrian Piper
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics IBrian Piper
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNSBrian Piper
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part IIBrian Piper
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part IBrian Piper
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part IIBrian Piper
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part IBrian Piper
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain InjuryBrian Piper
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromeBrian Piper
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadacheBrian Piper
 
Pathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseasePathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseaseBrian Piper
 
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Brian Piper
 
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIPathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIBrian Piper
 

Plus de Brian Piper (20)

Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
 
Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013Drug abuse and society drug presentations: Spring 2013
Drug abuse and society drug presentations: Spring 2013
 
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part IISedative & Hypnotic Drugs Part II
Sedative & Hypnotic Drugs Part II
 
Sedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part ISedative & Hypnotic Agents Part I
Sedative & Hypnotic Agents Part I
 
Agents for Bipolar
Agents for BipolarAgents for Bipolar
Agents for Bipolar
 
Psychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSDPsychopharmacology of Anxiety: Part II OCD & PTSD
Psychopharmacology of Anxiety: Part II OCD & PTSD
 
Antipsychotics Part II
Antipsychotics Part IIAntipsychotics Part II
Antipsychotics Part II
 
Antipsychotics I
Antipsychotics IAntipsychotics I
Antipsychotics I
 
Anti Inflammation agents for CNS
Anti Inflammation agents for CNSAnti Inflammation agents for CNS
Anti Inflammation agents for CNS
 
Antidepressants Part II
Antidepressants Part IIAntidepressants Part II
Antidepressants Part II
 
Antidepressants Part I
Antidepressants Part IAntidepressants Part I
Antidepressants Part I
 
Anticonvulsants Part II
Anticonvulsants Part IIAnticonvulsants Part II
Anticonvulsants Part II
 
Anticonvulsants Part I
Anticonvulsants Part IAnticonvulsants Part I
Anticonvulsants Part I
 
Agents for Brain Injury
Agents for Brain InjuryAgents for Brain Injury
Agents for Brain Injury
 
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg SyndromePathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
 
Pathophysiology: Migraine & Headache
Pathophysiology: Migraine & HeadachePathophysiology: Migraine & Headache
Pathophysiology: Migraine & Headache
 
Pathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's DiseasePathophysiology: Alzheimer's Disease
Pathophysiology: Alzheimer's Disease
 
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Introduction to Neuropsychiatry
 
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part IIPathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part II
 
Antiemetics
AntiemeticsAntiemetics
Antiemetics
 

Dernier

Exploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with MilvusExploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with MilvusZilliz
 
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodJuan lago vázquez
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingEdi Saputra
 
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...apidays
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...Zilliz
 
CNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In PakistanCNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In Pakistandanishmna97
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...DianaGray10
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FMESafe Software
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Victor Rentea
 
WSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAndrey Devyatkin
 
Introduction to Multilingual Retrieval Augmented Generation (RAG)
Introduction to Multilingual Retrieval Augmented Generation (RAG)Introduction to Multilingual Retrieval Augmented Generation (RAG)
Introduction to Multilingual Retrieval Augmented Generation (RAG)Zilliz
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native ApplicationsWSO2
 
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...Angeliki Cooney
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FMESafe Software
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century educationjfdjdjcjdnsjd
 
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWEREMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWERMadyBayot
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoffsammart93
 
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxCorporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxRustici Software
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Jeffrey Haguewood
 

Dernier (20)

Exploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with MilvusExploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with Milvus
 
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
 
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
Apidays New York 2024 - APIs in 2030: The Risk of Technological Sleepwalk by ...
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
 
CNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In PakistanCNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In Pakistan
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
 
WSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering Developers
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
Introduction to Multilingual Retrieval Augmented Generation (RAG)
Introduction to Multilingual Retrieval Augmented Generation (RAG)Introduction to Multilingual Retrieval Augmented Generation (RAG)
Introduction to Multilingual Retrieval Augmented Generation (RAG)
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
 
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWEREMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxCorporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptx
 
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
Web Form Automation for Bonterra Impact Management (fka Social Solutions Apri...
 

Neuropharmacology: Neurotransmission

  • 1. Neurocommunication Brian J. Piper, Ph.D.
  • 2. Terminology • Neurotransmitter: chemical that is released in the brain and has an effect on a local target • Hormone: chemical that is released into bloodstream that has an effect on a distant target
  • 3. Goals • Neurotransmission – History – Onset: Neurotransmitter release (classical and non-classical) – Offset: autoreceptors, transporters, enzymes – Receptor Families • Endocrine
  • 4. History: Golgi vs. Cajal • Italian physician • Reticulum theory • Silver stain Camillo Golgi (1843-1926)
  • 5. Controversy: Golgi vs. Cajal • Santiogo Ramon y Cajal – Neuroanatomist – Used Golgi’s technique – Neuron theory 1852-1934 Chicken cerebellum
  • 6. Neural Communication The body’s information system is built from billions of interconnected cells called neurons. Communication between neurons is both electrical and chemical.
  • 7. Otto Loewi • Discovered “Vagusstoff” later known as acetylcholine • “father of neuroscience” • Nobel Prize 1936
  • 8. What are amino acids? • Amine (NH2) + Carboxyl ( -COOH) • 20 total, 9 essential tyrosine Tryptophan
  • 9. More terminology • Peptides: short (<50) strings of amino acids, Valine-Glycine-Serine-Alanine… e.g. NPY C terminal: COOH N terminal: NH2 Arginine, Proline, Lysine, Phenylalanine, Methionine, Histidine, Aspartic Acid, Valine
  • 10. More terminology • Peptides: short (<50) strings of amino acids, Valine-Glycine-Serine-Alanine… e.g. NPY
  • 11. More terminology Proteins: longer strings of amino acids, have 3-D structure, form receptors, transporters
  • 12. Comparison Peptide Protein Size (amino acids) < 40 >40 Dimensions 1-D 3-D Complexity Low High Hemoglobin
  • 14. Electron Microscope • Beams of electrons are presented to a thin section, 50 pm (10-12) resolution • Reveals different types of Synapses
  • 18. Neurotransmitter Criteria • 1) Found and made presynaptically. • 2) Mechanism for inactivation. • 3) Stimulating neuron releases it. • 4) Receptors found postsynaptically. • 5) Applying substance has biological effect. • 6) Antagonizing inhibits biological effect. “neuromodulators”
  • 19. Neurotransmitter Comparison Classical Non-Classical Discovery 1950’s 1980’s Concentration High Low # Few Many Synthesis Anywhere Soma
  • 20. Classical Neurotransmitters • Monoamines: dopamine, norepinephrine, serotonin • Acetylcholine (ACh) • Amino Acids: glycine, GABA, Glutamate
  • 21. Non-classical Neurotransmitters • Peptides: Corticotropin-releasing factor (CRF), endorphins • Lipids: Anandamide • Gases: Nitric Oxide
  • 22. Co-Transmitters Amine/Amino Acid Peptide Dopamine Cholecystokinin (CCK) Norepinephrine enkephalin Epinephrine neurotensin Serotonin substance P Acetylcholine somatostatin Gamma aminobutyric acid (GABA) motilin Stahl, S. (2000). Essential Psychopharmacology, p. 20.
  • 24. Brakes II • Autoreceptors: this receptor (“auto” = “self”) can act to inhibit further neurotransmitter release – Terminal (axon) autoreceptors: inhibit neurotransmitter release – Somatodendritic autoreceptors: reduce rate of action potentials
  • 25. Brakes I • Enzyme: A + B __ENZ____> AB • Enzyme: CD __ENZ____> C + D
  • 26. Transporters • Proteins that move molecule from one place to another, examples: – SERT: serotonin transporter – NET: norepinephrine transporter – DAT: dopamine transporter Inside ---------------------------------------------------------------------- Outside
  • 27.
  • 28. Post-synaptic • Ligand: substance that binds to a receptor • Ion: atom where # electrons ≠ # protons – Ca2+ Na+ K+ – Cl- • First messenger: neurotransmitter • Second messenger: other molecule • Kinase: enzyme that adds phosphate (PO4)
  • 30. So Many Receptors! Serotonin (5-HT): 1 2 3 4 5 6 7
  • 31. Family 1: Ionotropic • Binding to receptor opens channel to let ions in (aka: ligand gated ion receptors)
  • 32. Family 1: Ionotropic • Binding to receptor opens channel to let ions in (aka: ligand gated ion receptors) 0:40 – 6:20: http://www.youtube.com/watch?v=8jPH2pKzIDY
  • 33. Family 2: Metabotropic (2nd messenger) • Steps: • 1) Ligand binds receptor • 2) G protein acts on enzyme • 3) Enzyme regulates 2nd messenger • 4) 2nd messenger acts on protein kinase 6:30-9:00 http://www.youtube.com/watch?v=8jPH2pKzIDY
  • 34. Family 2: Metabotropic (Channel) • Steps: • 1) Ligand binds receptor • 2) G protein alters channel • 3) ions flow out of neuron
  • 35. Receptor Families Compared Ionotropic Metabotropic Subunits 4-5 1 Mechanism Simple: Channel opening Complex: G protein cascade 2nd messengers No Yes Speed Fast Slow Meyer & Quenzer (2005). p 73
  • 36. Family 3: Tyrosine Kinase • Steps: 1) Ligand (BDNF) binds to Trk receptor 2) Trk receptors come together, and phosphorylate each other
  • 37.
  • 38. So many drug targets!!! Examples: 1) Tryptophan 6) Nicotine 10) MAO-I 11) SSRIs
  • 39. Endocrine System Gland Hormone (Function) Pineal Melatonin (light-dark rhythm) Thyroid T3/T4 (energy) Adrenal Cortisol (stress) Pancreas Insulin (glucose) Ovaries Estrogens (2nd sex characteristics) Testes Androgens (2nd sex characteristics)
  • 40. Example • Rats that received ecstasy (MDMA) during adolescence were more sensitive to a 5-HT2 agonist when adults Biezonski et al. (2009). Brain Research, 1252, 87-93.